On May 2020, the FDA granted breakthrough therapy designation to trastuzumab deruxtecan for the treatment of patients with metastatic and pretreated NSCLC whose tumours have a HER2 mutation. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.